Evolutionary Genomics Stock Analysis
| FNAM Stock | USD 0.0002 0.00 0.00% |
Evolutionary Genomics holds a debt-to-equity ratio of 1.807. Evolutionary Genomics' financial risk is the risk to Evolutionary Genomics stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Evolutionary Genomics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Evolutionary Genomics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Evolutionary Pink Sheet's retail investors understand whether an upcoming fall or rise in the market will negatively affect Evolutionary Genomics' stakeholders.
For many companies, including Evolutionary Genomics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Evolutionary Genomics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Evolutionary Genomics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Evolutionary Genomics' debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Evolutionary Genomics is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Evolutionary Genomics to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Evolutionary Genomics is said to be less leveraged. If creditors hold a majority of Evolutionary Genomics' assets, the Company is said to be highly leveraged.
Evolutionary Genomics is overvalued with Real Value of 1.68E-4 and Hype Value of 2.0E-4. The main objective of Evolutionary Genomics pink sheet analysis is to determine its intrinsic value, which is an estimate of what Evolutionary Genomics is worth, separate from its market price. There are two main types of Evolutionary Genomics' stock analysis: fundamental analysis and technical analysis.
The Evolutionary Genomics pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Evolutionary |
Evolutionary Pink Sheet Analysis Notes
About 33.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.53. Evolutionary Genomics had not issued any dividends in recent years. The entity had 16:1000 split on the 19th of October 2015. Evolutionary Genomics, Inc., together with its subsidiaries, engages in the research and identification of positively selected genes in humans, animals, and commercial crops. Evolutionary Genomics, Inc. was incorporated in 1990 and is based in Castle Rock, Colorado. Evolutionary Genomics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 2 people.The quote for Evolutionary Genomics is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To learn more about Evolutionary Genomics call Steve Warnecke at 720 900 8666 or check out https://www.evolgen.com.Evolutionary Genomics Investment Alerts
| Evolutionary Genomics generated a negative expected return over the last 90 days | |
| Evolutionary Genomics has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (2.79 M) with loss before overhead, payroll, taxes, and interest of (1.23 M). | |
| Evolutionary Genomics currently holds about 897.78 K in cash with (1.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.14, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 33.0% of the company shares are held by company insiders |
Evolutionary Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.66 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Evolutionary Genomics's market, we take the total number of its shares issued and multiply it by Evolutionary Genomics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
Evolutionary Genomics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Evolutionary Genomics Price Movement Analysis
The output start index for this execution was fourty-nine with a total number of output elements of twelve. The Moving Average is predictive technique used to analyze Evolutionary Genomics price data points by creating a series of averages of different subsets of Evolutionary Genomics entire price series.
Evolutionary Genomics Outstanding Bonds
Evolutionary Genomics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Evolutionary Genomics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Evolutionary bonds can be classified according to their maturity, which is the date when Evolutionary Genomics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Evolutionary Genomics Debt to Cash Allocation
Many companies such as Evolutionary Genomics, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Evolutionary Genomics currently holds 3.74 M in liabilities with Debt to Equity (D/E) ratio of 1.81, which is about average as compared to similar companies. Evolutionary Genomics has a current ratio of 9.65, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Evolutionary Genomics until it has trouble settling it off, either with new capital or with free cash flow. So, Evolutionary Genomics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Evolutionary Genomics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Evolutionary to invest in growth at high rates of return. When we think about Evolutionary Genomics' use of debt, we should always consider it together with cash and equity.Evolutionary Genomics Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Evolutionary Genomics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Evolutionary Genomics, which in turn will lower the firm's financial flexibility.Evolutionary Genomics Corporate Bonds Issued
About Evolutionary Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Evolutionary Genomics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Evolutionary shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Evolutionary Genomics. By using and applying Evolutionary Pink Sheet analysis, traders can create a robust methodology for identifying Evolutionary entry and exit points for their positions.
Evolutionary Genomics, Inc., together with its subsidiaries, engages in the research and identification of positively selected genes in humans, animals, and commercial crops. Evolutionary Genomics, Inc. was incorporated in 1990 and is based in Castle Rock, Colorado. Evolutionary Genomics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 2 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Evolutionary Genomics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Equity Search Now
Equity SearchSearch for actively traded equities including funds and ETFs from over 30 global markets |
| All Next | Launch Module |
Other Information on Investing in Evolutionary Pink Sheet
Evolutionary Genomics financial ratios help investors to determine whether Evolutionary Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Evolutionary with respect to the benefits of owning Evolutionary Genomics security.